{"id":"NCT03546816","sponsor":"Vyne Therapeutics Inc.","briefTitle":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-02","primaryCompletion":"2020-01-14","completion":"2020-02-14","firstPosted":"2018-06-06","resultsPosted":"2020-09-07","lastUpdate":"2021-05-20"},"enrollment":285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pruritus","Prurigo Nodularis"],"interventions":[{"type":"DRUG","name":"5mg Serlopitant Tablets","otherNames":["VPD-737"]},{"type":"DRUG","name":"Placebo Tablets","otherNames":[]}],"arms":[{"label":"5 mg Serlopitant Tablets","type":"EXPERIMENTAL"},{"label":"Matching Placebo Tablets","type":"PLACEBO_COMPARATOR"}],"summary":"Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis","primaryOutcome":{"measure":"Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10","timeFrame":"At Week 10","effectByArm":[{"arm":"Serlopitant 5 mg","deltaMin":26.45,"sd":null},{"arm":"Placebo","deltaMin":20.31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.229"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":139},"commonTop":["Upper respiratory tract infection","Pruritus"]}}